Valerio Therapeutics

ALVIO

FR0010095596

Pharmaceuticals

Real-time Euronext Paris Other stock markets 09:04:31 2024-05-17 am EDT			5-day change	1st Jan Change
0.1082 ^EUR	+0.19%		-5.91%	-34.42%

Apr. 30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Onxeo Sa Reports Earnings Results for the Half Year Ended June 30, 2021

July 29, 2021 at 12:30 pm EDT

Onxeo SA announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 589,000 compared to EUR 1.082 million a year ago. Net loss was EUR 4.770 million compared to net income of EUR 5.042 million a year ago.

Latest news about Valerio Therapeutics

Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Onxeo SA has Changed its Name to Valerio Therapeutics	23-06-06	CI
Biophytis' Finance Chief Resigns; Onxeo Exec Named Successor	23-05-02	MT
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Onxeo: share price rises after development update	23-01-26	CF
Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM	23-01-25	CI
Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors	22-11-30	CI
Onxeo SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-13	CI
Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie	22-09-01	CI
Onxeo Wins Bourse Approval To Delist From Denmark's Nasdaq First North Market	22-08-31	MT
Onxeo Shareholders OK Delisting From Denmark's Nasdaq First North Market	22-08-18	MT
Onxeo Wins US FDA's Approval To Conduct First Early-stage Study In Solid Tumors	22-07-01	MT
Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA	22-06-30	CI
Onxeo S.A. Appoints Khalil Barrage as New Board Member	22-06-16	CI
French Biotechnology Company Onxeo Names Chair as President/CEO	22-04-07	MT
Onxeo S.A. Announces the Appointment of Dr. Shefali Agarwal as President	22-04-07	CI
Onxeo S.A. Announces Executive Changes	22-04-07	CI
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-06	CI
Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022	22-03-31	CI
Onxeo's DNA Repair Inhibitor Shows Potential in Treating Homologous Recombination Proficient Tumors	22-03-09	MT
Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors	22-03-09	CI
Onxeo Names Interim CEO	22-01-03	MT
Onxeo S.A. Appoints Julien Miara as Interim CEO	22-01-03	CI
Onxeo SA Announces New Preclinical Data Confirm the Ability of Asidna™ to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments	21-12-08	CI

Chart Valerio Therapeutics

Duration

Period

More charts

Company Profile

Valerio Therapeutics (formerly Onxeo) is a clinical-stage biotechnology company developing novel cancer drugs by targeting tumor DNA functions through unparalleled mechanisms of action in the highly sought-after field of DNA damage response (DDR). The company focuses on the development of innovative first-in-class or disruptive compounds (in-house, acquired or licensed) from translational research to human clinical proof of concept. Valerio Therapeutics has platON®, its proprietary decoy oligonucleotide chemistry platform. It is dedicated to the generation of innovative new compounds to enrich the company's product portfolio. AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.108 EUR

Average target price

1.2 EUR

Spread / Average Target

+1,011.11%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VALERIO THERAPEUTICS	-34.42%	18.09M
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+29.78%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.53%	239B
ROCHE HOLDING AG	-3.15%	209B
NOVARTIS AG	+10.11%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals

Valerio Therapeutics

Equities

ALVIO

FR0010095596

Pharmaceuticals

Onxeo Sa Reports Earnings Results for the Half Year Ended June 30, 2021

Latest news about Valerio Therapeutics

Chart Valerio Therapeutics

Company Profile

Income Statement Evolution

Analysts' Consensus

Annual profits - Rate of surprise

Sector Other Pharmaceuticals